Latest drug consultation and price inquiry for capmatinib in 2024!

Capmatinib (Capmatinib) is a targeted therapy drug developed by Novartis (Novartis Pharmaceuticals). It is mainly used to treat non-small cell lung cancer (NSCLC). As an innovative drug, capmatinib is developed to respond to specific cases caused by abnormal expression or gene mutations of MET (tyrosine kinase) in lung cancer.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.

METis a protein involved in cell growth, differentiation and migration. In some cancers, abnormal activation of the MET pathway may lead to the development of tumors. The mechanism of action of capmatinib is to selectively inhibit the activity of MET kinase, thereby interfering with abnormal cell signaling and inhibiting the growth and spread of lung cancer cells.

Capmatinib is usually given as an oral medication that can be administered at home. The drug's research and development and clinical trials have achieved a series of positive results, especially in patients with MET-driven non-small cell lung cancer, showing significant efficacy.

Patients should closely follow their doctor's advice when using capmatinib and receive regular medical monitoring to ensure the efficacy and safety of the drug. At the same time, doctors will develop an individualized treatment plan based on the patient's genotype and specific condition to maximize the treatment effect and reduce potential adverse reactions.